Nuclear Imaging Institute
Nuclear Imaging Institute
Englewood, New Jersey, United States7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ultralow Dose PET Imaging of 18F-FDOPA | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, basal ganglia disorder, brain disorder, central nervous system disorder, epithelial neoplasm, glioma, movement disorder, neoplasm, nervous system disorder, neuroepithelial neoplasm, parkinsonian disorder, primitive neuroectodermal tumor | Enrolling by invitation | Phase 2 | 2026-04-21 | NCT07542158 | |
| Ultralow Dose PET Imaging of 18F-flurpiridaz | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Enrolling by invitation | Phase 2 | 2026-04-13 | NCT07284576 | |
| Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Mild Cognitive Impairment, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 2 | 2026-04-13 | NCT07012993 | |
| Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake | neoplasm | Recruiting | Phase 2 | 2026-04-08 | NCT07284589 | |
| Ultralow Dose PET Imaging for 18F-NaF Uptake | arthritic joint disease, arthropathy, musculoskeletal system disorder | Recruiting | Phase 2 | 2025-12-16 | NCT07284563 | |
| Ultralow Dose PET Imaging of 18F-FDG Uptake | cancer, neoplasm | Recruiting | Phase 2 | 2025-06-04 | NCT06956391 | |
| Ultralow Dose PET Imaging for PSMA Expression | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2025-06-04 | NCT06904313 |